Altimmune Inc (ALT)
6.74
0.00 (0.00%)
USD |
NASDAQ |
Nov 01, 16:00
6.70
-0.04
(-0.59%)
After-Hours: 20:00
Altimmune Enterprise Value: 314.11M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 314.11M |
| October 31, 2024 | 314.11M |
| October 30, 2024 | 315.53M |
| October 29, 2024 | 358.17M |
| October 28, 2024 | 333.30M |
| October 25, 2024 | 310.56M |
| October 24, 2024 | 315.89M |
| October 23, 2024 | 312.69M |
| October 22, 2024 | 318.37M |
| October 21, 2024 | 325.48M |
| October 18, 2024 | 324.06M |
| October 17, 2024 | 317.66M |
| October 16, 2024 | 322.64M |
| October 15, 2024 | 335.43M |
| October 14, 2024 | 292.08M |
| October 11, 2024 | 282.84M |
| October 10, 2024 | 262.94M |
| October 09, 2024 | 269.34M |
| October 08, 2024 | 278.58M |
| October 07, 2024 | 268.63M |
| October 04, 2024 | 277.86M |
| October 03, 2024 | 272.18M |
| October 02, 2024 | 280.71M |
| October 01, 2024 | 282.13M |
| September 30, 2024 | 271.47M |
| Date | Value |
|---|---|
| September 27, 2024 | 294.92M |
| September 26, 2024 | 319.09M |
| September 25, 2024 | 332.59M |
| September 24, 2024 | 341.12M |
| September 23, 2024 | 346.80M |
| September 20, 2024 | 388.74M |
| September 19, 2024 | 373.10M |
| September 18, 2024 | 363.15M |
| September 17, 2024 | 373.10M |
| September 16, 2024 | 373.81M |
| September 13, 2024 | 395.13M |
| September 12, 2024 | 339.70M |
| September 11, 2024 | 344.67M |
| September 10, 2024 | 329.75M |
| September 09, 2024 | 288.52M |
| September 06, 2024 | 275.73M |
| September 05, 2024 | 289.24M |
| September 04, 2024 | 297.05M |
| September 03, 2024 | 288.52M |
| August 30, 2024 | 311.27M |
| August 29, 2024 | 304.87M |
| August 28, 2024 | 295.63M |
| August 27, 2024 | 311.27M |
| August 26, 2024 | 322.64M |
| August 23, 2024 | 328.32M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-33.51M
Minimum
Aug 25 2023
984.81M
Maximum
Jul 20 2020
244.43M
Average
249.03M
Median
Apr 21 2021
Enterprise Value Benchmarks
| Eli Lilly and Co | 805.11B |
| Viking Therapeutics Inc | 7.191B |
| Amgen Inc | 222.98B |
| Avid Bioservices Inc | 775.66M |
| NovaBay Pharmaceuticals Inc | 3.615M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.64M |
| Revenue (Quarterly) | 0.005M |
| Total Expenses (Quarterly) | 26.75M |
| EPS Diluted (Quarterly) | -0.35 |
| Profit Margin (Quarterly) | -492.8K% |
| Earnings Yield | -24.33% |
| Normalized Earnings Yield | -24.33 |